(Bizalimogene ralaplasmid + mavilimogene ralaplasmid) is under clinical development by Inovio Pharmaceuticals and currently in Phase III for Human Papillomavirus (HPV) Associated Cancer. According to GlobalData, Phase III drugs for Human Papillomavirus (HPV) Associated Cancer have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Bizalimogene ralaplasmid + mavilimogene ralaplasmid)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Bizalimogene ralaplasmid + mavilimogene ralaplasmid) overview
VGX-3100 (a fixed dose combination of Bizalimogene ralaplasmid (pGX3002) and mavilimogene ralaplasmid (pGX3001)) is under development for the treatment of HPV associated anal dysplasia, cervical intraepithelial neoplasia 2/3 (CIN2/3) and vulvar intraepithelial neoplasia (VIN). VGX-3100 is a therapeutic DNA vaccine candidate administered as intramuscular injection. It targets the E6 and E7 oncogenic proteins of Type 16 and Type 18 HPV. It is based on SynCon DNA plasmid technology, ASPIRE technology and delivered using Cellectra electroporation Delivery System.
Inovio Pharmaceuticals overview
Inovio Pharmaceuticals (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its product pipeline includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL; INO-5401 for glioblastoma; and INO-3107 for recurrent respiratory papillomatosis (RRP). The company is also engaged in development programs in partnership with several companies and government bodies to develop therapeutics for infectious diseases such as HIV, Ebola, Zika virus, Middle East respiratory syndrome (MERS), Lassa fever and COVID-19. Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.
For a complete picture of (Bizalimogene ralaplasmid + mavilimogene ralaplasmid)’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.